Source comparison
Thymosin Alpha-1 HIV Support: Dosing Protocol Comparison
Standard Adjunct 1.6mg SC twice weekly 24–48 weeks +112 cells/μL Patients with CD4 <350 despite ART Most evidence supports this protocol. Well-tolerated, consistent outcomes Intensive Reconstitution 3.2mg SC twice weekly 12–24 weeks +148 cells/μL Severe immune
This comparison does not assign a generated winner or score.
- Standard Adjunct
- 1.6mg SC twice weekly
- 24–48 weeks
- +112 cells/μL
- Patients with CD4 <350 despite ART
- Most evidence supports this protocol. Well-tolerated, consistent outcomes
- Intensive Reconstitution
- 3.2mg SC twice weekly
- 12–24 weeks
- +148 cells/μL
- Severe immune depletion (CD4 <200)
- Higher dose shows benefit in advanced disease but doubles cost without proportional CD4 gain
- Maintenance Protocol
- 1.6mg SC once weekly
- Ongoing (>48 weeks)
- +68 cells/μL sustained
- Long-term immune support post-reconstitution
- Used after initial 24-week course. Prevents CD4 decline but less robust than twice-weekly dosing
- Pulsed Therapy
- 1.6mg SC twice weekly, 12 weeks on / 12 weeks off
- Cyclic indefinitely
- +94 cells/μL (averaged across cycles)
- Cost management in resource-limited settings
- Off-periods show partial CD4 decline. Continuous dosing preferred if feasible
- The twice-weekly 1.6mg subcutaneous protocol is the evidence-based standard. Higher doses (3.2mg) were tested in early trials but showed diminishing returns. The thymus has a functional ceiling for T-cell output that additional peptide can't override. Weekly dosing is less effective because the peptide's half-life is approximately 2–3 hours, and thymic signaling requires sustained stimulation over the dosing interval.